Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AL-273
- Development stage
- Preclinical
- Lead developer
- Alaw Therapeutics
- Modality
- Small Molecules
01
Overview
AL-273 is a next-generation, brain- and lung-penetrable, reversible small-molecule inhibitor of pan-mutant epidermal growth factor receptor (EGFR). Developed by Alaw Therapeutics, a subsidiary of Eilean Therapeutics, the compound is designed to target a broad spectrum of clinically relevant EGFR mutations, including difficult-to-treat and resistance-associated variants. By achieving robust central nervous system (CNS) and pulmonary penetration, AL-273 aims to provide durable pathway suppression and address therapeutic resistance in genetically diverse EGFR-driven solid tumors, particularly those with intracranial involvement or brain metastases. It is currently in preclinical development.
02
Targets
Beyond the preview
Go deeper on AL-273.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AL-273.